276 related articles for article (PubMed ID: 23527888)
1. Individualized therapy for metastatic colorectal cancer.
Silvestri A; Pin E; Huijbers A; Pellicani R; Parasido EM; Pierobon M; Petricoin E; Liotta L; Belluco C
J Intern Med; 2013 Jul; 274(1):1-24. PubMed ID: 23527888
[TBL] [Abstract][Full Text] [Related]
2. Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer.
Laurent-Puig P; Cayre A; Manceau G; Buc E; Bachet JB; Lecomte T; Rougier P; Lievre A; Landi B; Boige V; Ducreux M; Ychou M; Bibeau F; Bouché O; Reid J; Stone S; Penault-Llorca F
J Clin Oncol; 2009 Dec; 27(35):5924-30. PubMed ID: 19884556
[TBL] [Abstract][Full Text] [Related]
3. Relationship between colorectal cancer biomarkers and response to epidermal growth factor receptor monoclonal antibodies.
Hawkes E; Cunningham D
J Clin Oncol; 2010 Oct; 28(28):e529-31; author reply e532-e533. PubMed ID: 20679615
[No Abstract] [Full Text] [Related]
4. The forest and the trees: pathways and proteins as colorectal cancer biomarkers.
Bertagnolli MM
J Clin Oncol; 2009 Dec; 27(35):5866-7. PubMed ID: 19884524
[No Abstract] [Full Text] [Related]
5. Comparison of neuroendocrine differentiation and KRAS/NRAS/BRAF/PIK3CA/TP53 mutation status in primary and metastatic colorectal cancer.
Kleist B; Kempa M; Novy M; Oberkanins C; Xu L; Li G; Loland C; Poetsch M
Int J Clin Exp Pathol; 2014; 7(9):5927-39. PubMed ID: 25337237
[TBL] [Abstract][Full Text] [Related]
6. Are we ready to restrict EGFR therapy to quadruple-negative colorectal cancer?
Hawkes E; Cunningham D
Lancet Oncol; 2010 Nov; 11(11):1020-1. PubMed ID: 21051017
[No Abstract] [Full Text] [Related]
7. Analysis of KRAS, BRAF, PTEN, IGF1R, EGFR intron 1 CA status in both primary tumors and paired metastases in determining benefit from cetuximab therapy in colon cancer.
Park JH; Han SW; Oh DY; Im SA; Jeong SY; Park KJ; Kim TY; Bang YJ; Park JG
Cancer Chemother Pharmacol; 2011 Oct; 68(4):1045-55. PubMed ID: 21340604
[TBL] [Abstract][Full Text] [Related]
8. Combined assessment of epidermal [corrected] growth factor receptor dual color in situ hybridization and immunohistochemistry with downstream gene mutations in prediction of response to the anti-EGFR therapy for patients with metastatic colorectal cancer.
Takahashi N; Yamada Y; Taniguchi H; Honma Y; Iwasa S; Kato K; Hamaguchi T; Shimada Y
Arch Med Res; 2014 Jul; 45(5):366-74. PubMed ID: 24830936
[TBL] [Abstract][Full Text] [Related]
9. Using predictive biomarkers to select patients with advanced colorectal cancer for treatment with epidermal growth factor receptor antibodies.
Wong R; Cunningham D
J Clin Oncol; 2008 Dec; 26(35):5668-70. PubMed ID: 19001346
[No Abstract] [Full Text] [Related]
10. Predictive and prognostic factors in the complex treatment of patients with colorectal cancer.
László L
Magy Onkol; 2010 Dec; 54(4):383-94. PubMed ID: 21163770
[TBL] [Abstract][Full Text] [Related]
11. Prognostic vs predictive molecular biomarkers in colorectal cancer: is KRAS and BRAF wild type status required for anti-EGFR therapy?
Rizzo S; Bronte G; Fanale D; Corsini L; Silvestris N; Santini D; Gulotta G; Bazan V; Gebbia N; Fulfaro F; Russo A
Cancer Treat Rev; 2010 Nov; 36 Suppl 3():S56-61. PubMed ID: 21129611
[TBL] [Abstract][Full Text] [Related]
12. [Molecular predictive markers of EGFR-targeted therapy in metastatic colorectal cancer].
Fabian P; Berkovcová J
Cesk Patol; 2011 Oct; 47(4):154-8. PubMed ID: 22145213
[TBL] [Abstract][Full Text] [Related]
13. Predictive factors to targeted treatment in gastrointestinal carcinomas.
Silvestris N; Marech I; Brunetti AE; Azzariti A; Numico G; Cicero G; Delcuratolo S; De Luca R; Burz C; Lorusso V
Cancer Biomark; 2014; 14(2-3):151-62. PubMed ID: 24878816
[TBL] [Abstract][Full Text] [Related]
14. Is there a role for IGF1R and c-MET pathways in resistance to cetuximab in metastatic colorectal cancer?
Inno A; Di Salvatore M; Cenci T; Martini M; Orlandi A; Strippoli A; Ferrara AM; Bagalà C; Cassano A; Larocca LM; Barone C
Clin Colorectal Cancer; 2011 Dec; 10(4):325-32. PubMed ID: 21729677
[TBL] [Abstract][Full Text] [Related]
15. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.
Di Nicolantonio F; Martini M; Molinari F; Sartore-Bianchi A; Arena S; Saletti P; De Dosso S; Mazzucchelli L; Frattini M; Siena S; Bardelli A
J Clin Oncol; 2008 Dec; 26(35):5705-12. PubMed ID: 19001320
[TBL] [Abstract][Full Text] [Related]
16. The role of K-RAS and B-RAF mutations as biomarkers in metastatic colorectal cancer.
Selcukbiricik F; Erdamar S; Ozkurt CU; Molinas Mandel N; Demirelli F; Ozguroglu M; Tural D; Buyukunal E; Serdengecti S
J BUON; 2013; 18(1):116-23. PubMed ID: 23613396
[TBL] [Abstract][Full Text] [Related]
17. Targeting mechanisms of resistance to anti-EGF receptor therapy in KRAS wild-type colorectal cancer: the path to more personalized medicine.
Fakih M
Future Oncol; 2013 Apr; 9(4):551-60. PubMed ID: 23560377
[TBL] [Abstract][Full Text] [Related]
18. Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab.
Tol J; Dijkstra JR; Klomp M; Teerenstra S; Dommerholt M; Vink-Börger ME; van Cleef PH; van Krieken JH; Punt CJ; Nagtegaal ID
Eur J Cancer; 2010 Jul; 46(11):1997-2009. PubMed ID: 20413299
[TBL] [Abstract][Full Text] [Related]
19. Metastatic colorectal cancer: current state and future directions.
Fakih MG
J Clin Oncol; 2015 Jun; 33(16):1809-24. PubMed ID: 25918280
[TBL] [Abstract][Full Text] [Related]
20. KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer.
De Roock W; De Vriendt V; Normanno N; Ciardiello F; Tejpar S
Lancet Oncol; 2011 Jun; 12(6):594-603. PubMed ID: 21163703
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]